english version
Основан в 1944 году

Разделы:




Яндекс.Метрика

Новости:

05 Апрель,2003 | In a New Study Ziprasidone Demonstrated Fast Onset of Action in Significantly Reducing Symptoms of Acute Mania in Patients With Bipolar Disorder

NEW YORK, April 4 /PRNewswire-FirstCall/ -- Bipolar patients who received Pfizer Inc's atypical antipsychotic ziprasidone showed significant improvement in symptoms of acute mania compared with those who received placebo, according to data published today in the American Journal of Psychiatry. PR via NewsEdge Corporation : NEW YORK, April 4 /PRNewswire-FirstCall/ -- Bipolar patients who received Pfizer Inc's atypical antipsychotic ziprasidone showed significant improvement in symptoms of acute mania compared with those who received placebo, according to data published today in the American Journal of Psychiatry. Results from this randomized, double-blind, placebo-controlled study demonstrated that ziprasidone produced rapid, sustained improvements in manic symptoms when compared to placebo. Significant improvements were observed within two days of treatment and were maintained throughout the three-week study. The study, which involved 210 inpatients, also demonstrated that after 7 days of treatment ziprasidone-treated patients showed significant improvement across all evaluation scales compared to those who took placebo, including symptoms of acute mania, psychosis and social functioning. "Physicians are often looking for effective treatment options to help control the multiple symptoms of acute mania in patients who suffer from bipolar disorder," said Dr. Paul Keck, Professor of Psychiatry and Pharmacology and Vice Chairman for Research, Department of Psychiatry, University of Cincinnati College of Medicine. "This study suggests that ziprasidone may be a rapid and beneficial treatment option for bipolar mania." Bipolar disorder, which is also referred to as manic-depressive illness, is a serious form of mood disorder in which patients may experience extreme 'highs,' or manic episodes, and extreme 'lows,' or periods of major depression. The condition is estimated to affect one in every 100 Americans and has a major impact on the ability to function in daily life. Bipolar disorder is estimated to cost society about $45 billion per year. Patients in the midst of a period of mania, which usually lasts at least a week, may appear to be overly energetic, extremely expansive or excessively happy. They may have difficulty sleeping, functioning in social or work situations and may overindulge in pleasurable activities. The study was conducted in the United States and Brazil. Ziprasidone patients began taking 80 mg per day and were quickly titrated to 160 mg per day by the second day. Dosing was then flexible for the remainder of the study. Efficacy was measured using standardized psychiatric assessment scales. Among ziprasidone-treated patients, there was a low incidence of movement disorders, a side-effect associated with some atypical antipsychotic medications and no clinically significant weight gain, changes in vital signs or other safety parameters. The most common side effects of ziprasidone in this study included somnolence, headache, dizziness, hypertonia, nausea and akathisia. Discovered and developed by Pfizer, ziprasidone is a serotonin and dopamine antagonist. The medicine was approved by the U.S. Food and Drug Administration in February 2001 for use in the treatment of schizophrenia. It also is approved in more than 45 countries worldwide. Ziprasidone received approval for the treatment of acute mania in Brazil in November 2002. Pfizer plans to file a supplemental new drug application FDA later this year for the treatment of acute mania. Ziprasidone is currently marketed as Geodon in the United Sates and in Brazil. Oral ziprasidone is associated with a prolongation of the QTc interval of the electrocardiogram, an effect seen with certain other marketed medicines, including some antipsychotics. This effect was well characterized in the extensive oral ziprasidone trials database and is reflected in the FDA's product labeling, which suggest that physicians use their best judgment as to whether ziprasidone is the appropriate medication based on the overall status of the patient. Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best known consumer products. SOURCE Pfizer Inc -0- 04/04/2003 /CONTACT: Mariann Caprino of Pfizer Inc, +1-212-733-4554/ /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html / (PFE) CO: Pfizer Inc ST: New York IN: MTC HEA SU: AG -- NYF005 -- 2196 04/04/2003 08:00 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>

02 Апрель,2003 | Стриндберг и Ван Гог - Карл Ясперс

27 Март,2003 | Современные течения в психиатрии - Освальд Бумке

25 Март,2003 | Repligen Announces Open Label Extension of Phase 3 Clinical Trials of Synthetic Human Secretin in Children with Autism

WALTHAM, Mass., March 25 /PRNewswire-FirstCall/ -- Repligen Corporation announced today plans to initiate an open label extension of its ongoing Phase 3 clinical trials of synthetic human secretin in children with autism. PR via NewsEdge Corporation : WALTHAM, Mass., March 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today plans to initiate an open label extension of its ongoing Phase 3 clinical trials of synthetic human secretin (RG1068) in children with autism. In the extension phase of the study, all patients who complete the Phase 3 trials will be offered the option of treatment with RG1068 once every three weeks for 1 year. The goal of the Phase 3 Extension Study is to provide patients access to RG1068 and to collect additional, longer-term safety data. Each patient will be monitored for Adverse Events and changes in a variety of blood parameters throughout the Extension Study. "We are pleased to receive approval from the FDA for this open label extension of our Phase 3 clinical trials which was initiated at the request of some of the clinical investigators in our study," stated Walter C. Herlihy, President and CEO of Repligen. "This study will provide patients, including those who may have received the placebo in the Phase 3 study, access to RG1068 prior to the completion of the Phase 3 study." Data from the Phase 3 Extension Study will add to the extensive safety data already collected in the Phase 2 clinical trial, the Phase 2 Extension Study and the on-going Phase 3 clinical trials. To date there have been more than 1,000 administrations of RG1068 in children with autism without a serious adverse event. Extensive analyses of blood and urine chemistries have shown no indication of toxicity associated with administration of RG1068 and no patient has developed an antibody response to RG1068. About Repligen's Phase 3 Clinical Trial of RG1068 Repligen is currently enrolling children aged 2 years 8 months to 4 years 11 months with moderate to severe symptoms of autism into two Phase 3 clinical trials. Each patient is comprehensively evaluated at baseline, receives six injections of RG1068 or a placebo over 18 weeks, and is then reevaluated for improvements in the symptoms of autism. The primary endpoints for the trial are improvements in reciprocal social interaction as measured with the Autism Diagnostic Observation Schedule and the Clinical Global Impression of Change. Secondary endpoints include improvements in language and improvements in behavior. The trials are currently being carried out at approximately 20 medical centers in the United States. Information concerning participation in the Phase 3 clinical trials may be found on www.autismtrial.com. About Repligen Corporation Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of new drugs for pediatric developmental disorders including autism, immune and metabolic disorders. Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(tm) and SecreFlo(tm), the profits from which will be used to support the development of our proprietary products. rProtein A(tm) is a consumable reagent used by the pharmaceutical industry to produce a class of drugs called monoclonal antibodies and SecreFlo(tm), secretin for injection, is marketed to gastroenterologists for pancreatic assessment and for use during a gastrointestinal procedure called ERCP. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com. This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance, management's strategy, plans and objectives for future operations, clinical trials and results and product plans and performance such as the anticipated growth in the monoclonal antibody market and projected growth in product sales, constitute forward-looking statements. Such forward- looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein. Walter C. Herlihy, Ph.D. President and Chief Executive Officer (781) 250-0111, ext. 2000 David Walsey EURO RSCG Life NRP (212) 845-4257 SOURCE Repligen Corporation -0- 03/25/2003 /CONTACT: Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen, +1-781-250-0111, ext. 2000; or David Walsey of EURO RSCG Life NRP, +1-212-845-4257/ /Web site: http://www.repligen.com/ (RGEN) CO: Repligen Corporation ST: Massachusetts IN: MTC BIO SU: EO-CR -- NETU005 -- 0765 03/25/2003 07:59 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>

25 Март,2003 | Painkillers against alzheimer's disease

Scientists at the University of California have discovered that common painkillers may help dissolve the brain lesions - known as amyloid plaques - that are a hallmark of Alzheimer's disease. Scotland on Sunday via NewsEdge Corporation : Scientists at the University of California have discovered that common painkillers may help dissolve the brain lesions - known as amyloid plaques - that are a hallmark of Alzheimer's disease. Non-steroidal anti-inflammatory drugs, such as Ibuprofen, bind to these amyloid plaques, helping to destroy them and prevent the growth of new plaques. According to the researchers, this may explain why people who take anti-inflammatory medication over several years seem to be at lower risk for later development of Alzheimer's disease. In a separate study conducted at both Columbia University College of Physicians and Surgeons and Stanford University, doctors found that malfunctioning brain cells, called astrocytes, may be the culprits behind the accumulation of the amyloid proteins that cause plaque to form. Everyone makes this substance, but in people with Alzheimer's disease, the production process goes haywire. They either make too much or too little, or the substance itself is degraded. As a result, the proteins clump up, forming plaques, which then lead to the death of neutrons and dementia. Alzheimer's disease often begins with mild memory lapses, after which memory, language and most mental functions gradually deteriorate. Researchers at the London School of Economics say the number of people with cognitive impairment will rise by about 66 per cent. This shows a clear need to find widely available treatments that will delay the progression of dementia. Wouldn't it be great if the answer was already lurking at the back of your medicine cabinet? For more information, contact the Alzheimer's Society, Gordon House, 10 Greencoat Place, London, SW1P 1PH (020 7306 0606; enquiries alzheimers.org.uk) Publication: Scotland on Sunday Distributed by Financial Times Information Limited <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>

24 Март,2003 | Диссертации:

на заседании диссертационного совета НЦПЗ РАМН состоялась защита кандидатской диссертации

 

Состоялось представление к защите кандидатской диссертации Волель Б.А.

18 Март,2003 | First treatment in nine years approved for bipolar mania in Canada - Zyprexa(r) helps control the symptoms of mania and prevents relapse

TORONTO, March 18 /CNW/ - Today, Eli Lilly Canada Inc. announced that Zyprexa has been approved in Canada for the treatment of manic and mixed episodes associated with bipolar disorder, also known as manic depressive illness. Canada Newswire English via NewsEdge Corporation : TORONTO, March 18 /CNW/ - Today, Eli Lilly Canada Inc. announced that Zyprexa(r) (olanzapine) has been approved in Canada for the treatment of manic and mixed episodes associated with bipolar disorder, also known as manic depressive illness. Zyprexa is the first treatment in nine years approved for bipolar mania in Canada. Zyprexa provides rapid symptom control of a broad range of symptoms associated with mania and helps prevent relapse back into mania. "Zyprexa represents a significant advancement in the treatment of bipolar disorder," explains Dr. Roger McIntyre, Assistant Professor of Psychiatry at the University of Toronto. "A recent study showed that Zyprexa works better than Lithium, the current gold standard, in preventing manic episodes. In addition, ongoing studies show that Zyprexa manages both the manic and depressive phases of the illness." Bipolar disorder affects approximately one to two per cent of the adult population.(1) Bipolar disorder is a lifelong illness characterized by disruptive swings in mood--from euphoria and irritability (manic episodes), to periods of depression. A patient may experience either "pure" episodes (manic or depressive symptoms) or "mixed" episodes (a mixture of manic and depressive symptoms at the same time). In addition to the profound impact that the illness has on patients, there can be an equally severe impact on the patient's family and caregivers. Twenty-five to 50 per cent of people with bipolar disorder will attempt suicide at least once.(2) "When I'm in a manic phase my mind runs rapidly, I can't concentrate, I can become delusional and lose touch with reality. And in my depressed state nothing interests me. There seems no point in doing anything and everything seems too hard. It's overwhelming. Work is almost out of the question," explains Danny Marinus, bipolar patient. "It's awful for my family. They never know what mood I'll be in and what's going to happen next. Zyprexa has stabilized my mood and has helped me live a normal life again." "For patients, each day spent with manic or depressive symptoms can be devastating. Those afflicted with the illness suffer from severe mood swings to overwhelming feelings of sadness and low self-worth, which can include suicidal thoughts and even suicide," says Phil Upshall, President, Mood Disorders Society of Canada. "In addition to the profound impact that the illness has on patients, there can be an equally severe impact on the patient's family and caregivers. We welcome any new advancements that may help patients with bipolar disorder move forward with their lives." Clinical Trial Results In ongoing clinical trials with bipolar patients, Zyprexa has been shown to provide rapid symptom control, help patients remain in remission longer and help prevent relapse into mania: - Rapid symptom control in bipolar mania: studies show that Zyprexa demonstrated greater efficacy than placebo in the treatment of bipolar mania,(3,4) including a higher rate of response (65 per cent vs. 43 per cent respectively).(3) Zyprexa has been shown to produce a significantly greater improvement in symptoms of mania vs. divalproex(5) - Effective in depression symptoms: Zyprexa has been shown to manage depressive symptoms in patients with manic and mixed episodes. These symptoms are particularly resistant to standard anti-manic treatment. Nearly a seven-fold improvement in depressive symptoms was seen when Zyprexa was added to another mood stabilizer(6) - More effective than the current gold standard - lithium: a year-long study showed that in the maintenance treatment of bipolar disorder, patients taking Zyprexa relapsed into mania only half as often as patients taking lithium(6) Zyprexa is generally well tolerated. Adverse events reported in clinical trials included somnolence, dizziness and dry mouth, but rarely led to discontinuation of trial. As with other mood stabilizers, Zyprexa can also be associated with increased appetite leading to weight gain. The recommended beginning dose of Zyprexa to treat acute manic episodes is 10 milligrams in combination therapy or 15 milligrams by itself, taken once a day without regard to meals. Zyprexa is also indicated in Canada for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Since introduced in 1996, Zyprexa has been prescribed to nearly 11 million people worldwide. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Eli Lilly Canada, headquartered in Toronto, Ontario, employs more than 700 people across the country. Additional information about Eli Lilly Canada can be found at www.lilly.ca. NOTE TO EDITORS: Physician experts will be available for interviews in Toronto, Hamilton, Vancouver, Montreal and Moncton. NOTE TO TELEVISION STATIONS: B-Roll will be available on March 18th at the following coordinates: 10:00 am - 10:30 am (ET) and 13:30 pm - 14:00 pm (ET) Anik E2 C Band, Transponder 3B, Audio subcarrier 6.2 and 6.8 Downlink Frequency 3820 vertical References 1. Mood Disorders Society of Canada website, http://www.mooddisorderscanada.ca 2. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl 9):47-51 3. Tohen, M et al., Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000;57:841-849 4. Tohen M et al., Olanzapine vs. placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702-709 5. Tohen M et al., Olanzapine versus divalproex in the treatment of acute mania Am J Psychiatry 2002; 159:1011-1017. 6. Tohen M et al., Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blinded controlled 12-month clinical trial. Presented at the Third European Stanley Foundation Conference on Bipolar Disorder in Freiburg, Germany. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=86406 -0- 03/18/2003 /For further information: Please contact: Kent Hovey-Smith, Eli Lilly Canada, (416) 693-3879; Sabrina Paiva/Michelle Muise, GCI Group, (416) 486-2560/(416) 486-7272/ CO: ST: IN: SU: CNW 08:00e 18-MAR-03 <> << Copyright ©2003 Canada NewsWire >>

17 Март,2003 | Схизофрения - Освальд Бумке

Схизофрения - Освальд Бумке

13 Март,2003 | Душевные болезни в картинах и образах - Зиновьев П.М

13 Март,2003 | Drugs And Driving Danger

The RAC Foundation has urged the Government to undertake an urgent investigation into the possible connections between road safety and taking anti-depressants and to highlight the potential of impaired driving performance to users of the medications. Nottingham Evening Post via NewsEdge Corporation : The RAC Foundation has urged the Government to undertake an urgent investigation into the possible connections between road safety and taking anti-depressants and to highlight the potential of impaired driving performance to users of the medications. The use of anti-depressants has increased dramatically over the past decade. Between 1990 and 1995, the number of prescriptions for anti-depressants rose by 116, and for SSRIs (newer anti-depressants such as Prozac) in particular by 732, 2001 alone saw a ten per cent increase on the previous year in the number of anti-depressant prescriptions. A recent report commissioned by the Department of Transport also suggested that more research was needed to investigate the effects of new-generation anti-depressants on driving performance and accident risk. It recommended that additional studies were needed - including the testing of drivers involved in road accidents for the presence of drugs at the time instead of the more traditional method of using prescription records. It reasoned that definitive conclusions could only be made following further studies that would also look at dosage, duration and tolerance levels and interaction with other drugs and alcohol. Edmund King, executive director of the RAC Foundation, said: "There has been an alarming increase in depressive illness and the number of prescriptions. In the last recorded year (2001) there were around 30 million prescription items for anti-depressant medication in the UK. "There is considerable evidence that older generation anti-depressant drugs and tranquillisers have an adverse effect on driving and can increase the risk of accidents but not enough work has been done on the relationship between the newer forms of medication and driving. "While medical opinion certainly considers that driving performance is not impaired as much, we don't know that definitely. Little research has been done which studies the accident risk of these drugs. It is imperative that Government implements the recommendations of their report and undertakes conclusive research about the safety of anti-depressant drugs for motorists. Patients taking anti-depressant medications should monitor their own driving behaviour and be aware of the possibility that their driving abilities might be influenced by the drug or its side effects and act responsibly. If in any doubt drivers should consult their GP." RAC Foundation's medical consultant Dr Tony Lavelle said: "Different drugs prescribed for depression can lead to a variety of reactions in different individuals. Obviously patients prescribed new drugs should be advised whether it is safe to drive and should read the small print. Anyone prescribed new medication for depression should not drive for two or three days anyway, to ascertain their true reaction to the new drugs. Individuals suffering anxiety or depression without significant memory or concentration problems, agitation, behavioural disturbance or suicidal thoughts, need not inform DVLA and may continue to drive depending on their medication. Others suffering more severe anxiety should crease driving, pending the outcome of medical inquiry." Publication: Nottingham Evening Post Distributed by Financial Times Information Limited <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>








| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты